Original news and analysis on international IP policy
The World Health Organization Executive Board this week recommended the extension of an important strategy and plan of action on health, IP and innovation. It also set out steps to resolve questions over evaluation and review of the strategy and plan of action before the annual World Health Assembly in May.
The World Health Organization Executive Board has set a way forward from now to the annual May World Health Assembly for addressing the sensitive issue of drafting a framework for engagement with “non-state actors,” such as industry, foundations, academics and other non-governmental stakeholders.
In search of sustainable innovation models for cures for diseases affecting primarily developing countries, with the Ebola epidemic as a new reminder of the necessity and urgency of the matter, the World Health Organization had tasked an expert working group with the search for solutions. Last week, the WHO Executive Board took note of the progress made so far.
Welcome to (ANEPI), the first Intellectual Property News Agency of Ecuador. The Agencia de Noticias Especializada en Propiedad Intelectual (ANEPI) publishes news, analysis, interviews, feature articles, a weekly update and more on Ecuador and the region, at Articles are…
After long preparations, the Second Circuit Court of China’s Supreme People’s Court was officially instituted in Shenyang city, Liaoning province in northeast China on 31 January. Qiang Zhou, president and chief judge of China’s Supreme People’s Court, attended and addressed the nameplate unveiling ceremony of the Second Circuit Court.
It is no secret that the United States has been scaling up pressure on India to adopt intellectual property measures similar to those common in the United States and the European Union. But to what extent does India’s new government led by the business-friendly Narendra Modi see eye to eye with US official position? Can India, the “pharmacy of the world”, resolve the friction between pharmaceutical patents and access to affordable medicines without putting off foreign investors? The vitriolic and polarising debate surrounding these questions has got a fresh lease of life following US President Barack Obama’s landmark three-day visit to India this week.
While Indian and American business moguls are bullish about the future, Indian generic drug-makers as well as health activists within and outside India are deeply anxious about the shape of things to come
Intellectual property issues emerged at the World Health Organization Executive Board today as members discussed fake and substandard medicines, with some countries saying that the fight against such medicines should not serve as a pretext to enforce intellectual property rights and prevent access to safe generic medicines.
The World Health Organization Executive Board this week has addressed the relationship between the UN agency and its funders and lobbyists, examined the budget for the next biennium, and looked at the issue of the growing resistance of bacteria to…
A Geneva expert has offered his view on the top internet governance issues likely to come up in 2015. These include: cybersecurity, privacy, internet neutrality, and the proposed transition of control over a key underlying aspect of the internet.
Gavi, the Vaccine Alliance, boasted success this week as its biennial replenishment conference attracted US$ 7.5 billion in pledges, which is the organisation said is expected to allow 300 million additional children to be vaccinated in poor countries. The vaccine…
BEIJING - With the Beijing, Shanghai and Guangzhou Intellectual Property Courts being put into operation late last year, the rules for technical investigators had been missing until 21 January, when the Supreme People’s Court released the Provisional Regulations of the Supreme People’s Court on Several Issues concerning the Participation of Technical Investigators in Intellectual Property Court Proceedings. This is China’s first of its kind making rules for technical investigators.
Opposition proceedings in Europe have long served as a powerful tool for third parties to challenge the validity of a patent before the European Patent Office (EPO). Now, under the America Invents Act (effective September 2012), the United States (US) has two new procedures for challenging the validity of a patent before the US Patent and Trademark Office (USPTO): inter partes review (IPR) and post-grant review. Current statistics indicate a higher invalidation rate for IPRs as compared to EPO oppositions.